Table 1 Cohort characteristics
Cases (n = 148) | Controls (n = 32) | |
|---|---|---|
Mean age at delivery in years (SD) | 32.3 (3.8) | 32.0 (4.4) |
Median disease duration at delivery in years (range) | 8.0 (0.7 to 29.7) | - |
Number of nulliparous women, n (%) | 70/147 (47.6) | 14/32 (43.8%) |
Mean gestational age at delivery, weeks (range) | 39.3 (31.4 to 42.1) | 40.4 (34.0 to 42.0) |
Breastfeeding (six weeks postpartum), n (%) | 62/148 (41.9) | 27/32 (84.4) |
Anti-CCP positive, n (%) | 93/147 (63.3) | - |
Rheumatoid Factor (IgM) positive, n (%) | 108/148 (73.0) | - |
Erosive disease, n (%) | 43/147 (70.7) | |
DAS28-CRP3 >3.2 in first trimester, n (%) | 75 (61.5) | - |
Classification of disease activity during pregnancy | ||
good response/moderate response | 37/75 (49.3) | - |
no response | 38/75 (50.7) | - |
Classification of disease activity during postpartum period (early flare) | ||
severe deterioration/moderate deterioration (n, %) | 35/141* (24.8) | - |
no deterioration (n, %) | 106/141* (75.2) | - |
Classification of disease activity during postpartum period (late flare) | ||
severe deterioration/moderate deterioration (n, %) | 29/141* (20.6) | - |
no deterioration (n, %) | 112/141* (79.4) | - |
Median number of DMARDs (incl prednisone) prior to conceive (min-max) | 2 (0-7) | - |
No DMARD** use prior to conceive, n (%) | 7/147 (4.8) | |
Use of methotrexate prior to conceive, n (%) | 75/147 (51.0) | - |